OZMOSI announced the launch of a new global website which consolidates clinical trial data from all around the world into a single searchable database, GlobalClinicalTrialsData.com. This is a free, real-time, global resource with the ability to search more than 280,000 trials covering over 3,700 disease areas. By delivering a website that aggregates real-time trial data from clinical trial registries around the world into one single, easy-to-use publicly available website, OZMOSI has taken several large steps toward providing the industry and patients with ten times more downloadable clinical information than any other existing free global registry.
Any researcher, hospital, doctor, or patient, can now access real-time clinical trial data from around the world to research which drugs are being tested for a disease, what organization is running the trial, where it’s available, and dozens of other information points previously unavailable from any single database. The first version of GlobalClinicalTrialsData.com includes trials from the United States, Europe and Japan; China, Australia and New Zealand will be added by the end of 2017. In 2018, OZMOSI will provide access to 99 percent of all clinical trials around the world in a single, standardized, real-time stream that can be easily managed, sorted, and analyzed.
The database downloads data in a user-friendly format and offers ten times more downloadable trial information than any other free platform.
“There is an opportunity to fundamentally transform how the healthcare industry works,” said Beau Bush, founder of OZMOSI. “Setting profits aside and giving GlobalClinicalTrialsData.com to the world is the right thing to do because we believe that free data should be free for everyone. By offering real-time information, ten times more downloadable data than any other trial registry, and by removing download restrictions, GlobalClinicalTrialsData.com will provide greater industry transparency and incredible efficiencies, which will empower and encourage the industry to increase cooperation and collaboration on drug research like never before.”